Drugmaker Novo Nordisk bets $145 million on post-Brexit UK science

LONDON (Reuters) - Novo Nordisk, the world's top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.